Sertraline

ID: sertraline

Aliases: Zoloft

Type: compound

Route/form: oral

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, label

Linked sources: 4

Broad outcomes: Brain / mood / sleep

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• serotonin transporter inhibitor

Optimization domains

• anxiety
• depression
• panic
• OCD

Research basis

• Sertraline is an approved SSRI with randomized anxiety/depression evidence; in optimization terms it is relevant where anxiety is limiting sleep, training consistency, or function.
• The PANDA trial is useful because anxiety-symptom improvement can precede or exceed depression-score changes in primary-care patients.
• Compared with clomipramine, it is generally a lower-toxicity serotonergic first-line option.

Limits, risks, and missing evidence

• Delayed onset, activation, GI effects, sexual dysfunction, emotional blunting, withdrawal, and serotonin-syndrome interactions matter.
• It is not an acute fix for physical panic symptoms and can initially worsen agitation or sleep in some users.
• Combining with MAOIs, stimulants, serotonergic TCAs, or multiple sedatives raises risk.

Risk flags

• approved drug
• serotonergic
• sexual side effects
• withdrawal
• interaction risk

Linked papers, labels, and reviews

1. FDA label: Zoloft sertraline hydrochloride
   label / fda_sertraline_label
   Official label.
2. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder
   human_rct / pubmed_sertraline_gad_2004
   Randomized adult GAD trial; direct psychiatric indication-adjacent evidence for anxiety symptom reduction, not acute panic-attack rescue.
3. The clinical effectiveness of sertraline in primary care: the PANDA randomized trial
   human_rct / pubmed_sertraline_panda_2019
   Pragmatic double-blind placebo-controlled trial; relevant because anxiety symptoms improved earlier than depressive symptoms.
4. A double-blind study of the efficacy and safety of sertraline and clomipramine in severe major depression
   human_rct / pubmed_sertraline_clomipramine_depression_2000
   Head-to-head tolerability/efficacy comparison useful for explaining why clomipramine potency comes with a heavier adverse-effect burden.